1
|
Wei C, Yang X, Guo P, Chen X, Li C, Chen J, Zhou S. Myxoinflammatory Fibroblastic Sarcoma of the Parotid Gland: First Case Report and Literature Review. Front Med (Lausanne) 2022; 9:833822. [PMID: 35669919 PMCID: PMC9163338 DOI: 10.3389/fmed.2022.833822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Accepted: 04/22/2022] [Indexed: 11/13/2022] Open
Abstract
Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare, low-grade malignant soft tissue tumor. Most of the previously reported cases about this tumor were diagnosed within the soft tissues. Here, we report a unique case of MIFS of the right parotid gland in a 39-year-old Chinese male. The tumor primarily consisted of an inflammatory area and a mucus-like area in a migratory distribution. A number of lymphocytes, neutrophils, viral-like cells with large nucleoli, and eosinophilic cytoplasm or Reed-Sternberg-like cells, as well as spindle cells and epithelial-like aberrant cells, were observed within the tumor. They were found to express Vimentin and CD10 protein and no other specific immunohistochemical markers. The various cytomorphology and immunohistochemical features of this tumor were highly consistent with MIFS found in other sites. Therefore, several leading pathologists ultimately confirmed the final diagnosis of MIFS in the right parotid gland after repeated deliberation. To our knowledge, this is the first case of MIFS occurring in the parotid gland. Thus, our study provides a novel basis for identifying the biological behavior of the tumor in MIFS and also allows us to better understand the pathology of this rare tumor.
Collapse
Affiliation(s)
- Changhong Wei
- Department of Pathology, Guangxi Medical University Cancer Hospital, Nanning, China
- National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, China
| | - Xuejia Yang
- National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, China
| | - Pingping Guo
- Department of Ultrasound Imaging, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Xiaoyu Chen
- Department of Pathology, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Chunjun Li
- Department of Pathology, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Jun Chen
- Department of Pathology, Guangxi Medical University Cancer Hospital, Nanning, China
- *Correspondence: Jun Chen,
| | - Sufang Zhou
- National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, China
- Department of Biochemistry and Molecular Biology, School of Pre-clinical Science, Guangxi Medical University, Nanning, China
- Sufang Zhou,
| |
Collapse
|
2
|
Auw-Haedrich C, Mentzel T, Reinhard T. Myxoinflammatory fibroblastic sarcoma of the iris. Pathology 2017; 49:794-795. [PMID: 29079001 DOI: 10.1016/j.pathol.2017.08.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Revised: 07/26/2017] [Accepted: 08/03/2017] [Indexed: 10/18/2022]
Affiliation(s)
| | - Thomas Mentzel
- Dermatohistopathologische Gemeinschaftspraxis, Friedrichshafen, Germany
| | - Thomas Reinhard
- Eye Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| |
Collapse
|